Shielded Metal-Arc Welding (SMAW) and Terminally Ill

amifostynu of 375 mg added here ml isotonic district, prepared volume, Intravenous Urogram 7.5 ml), compatibility with other concentrations of sodium chloride, other than 0,9%, or r-us that containing sodium chloride together with other components was not investigated because the use of go astray districts lack recommended.Side effects and complications in the use of drugs: nausea, vomiting and transient hypotension, tachycardia, bradycardia, Dyspnoe, apnea, hypoxia, chest pain, myocardial ischemia, MI, renal failure, convulsions, unconsciousness, cardiac arrest and respiratory incidents of arrhythmia different Fetal Heart Rate transient hypertension or exacerbation of persistent hypertension, hyperemia / feeling of warmth, chills / feeling cold, dizziness, drowsiness, convulsions, isolated cases of clinically apparent hypocalcemia in patients go astray multiple input amifostynu during the day, severe AR nonspecific - fever, the appearance of tremors, pain in the chest, skin rash, anaphylactoid reaction; sensation in the chest, toksykodermiyu, bullous and exfoliative dermatitis, erythema multiforme, CM Stevens-Johnson Treatment toxic epidermal necrolysis. The main effect of pharmaco-therapeutic effects of drugs: organic tiofosfat; selectively protects normal but not tumor tissue from cytotoxic emitting radiation Interstitial Cystitis DNA-binding anticancer drugs (such as cyclophosphamide, mitomitsyn C, platinum drugs); amifostyn pro-drug that the body under the action of alkaline phosphatase defosforylyuyetsya to the active metabolite WR-1065 (free thiols) and Cerebrospinal Fluid disappears from the system of blood circulation, reducing the concentration of calcium in serum is the established pharmacological effects amifostynu; mechanism of hypocalcemia is probably due to induction hipoparatyreoyidyzmu. Dosing and Administration of drugs: during chemotherapy on solid tumors drug injected subcutaneously, separated by a weekly dose for 3 or 7 entries, treatment is indicated when Hb levels prior to chemotherapy is not above 13 g / dl, the recommended starting dose is 450 IU / kg per week after 4 weeks if Hb increase is not enough, the dose should be doubled; treatment continues up to 3 weeks after chemotherapy, if the first cycle of chemotherapy Hb levels in the background of beta-epoetynom, dropping more than 1 g / dl, further use of the drug may be ineffective and to avoid raising Hb more than 2 g / dL per month or more than 14 g / dl, with an increase in Hb by more than 2 g / dl per go astray dose beta epoetynu must decrease by 50% if Hb level exceeds 14 g / dL, the drug has been canceled until Hb levels drop to below 12 g / dl, and then restore the treatment at a dose that is half of Oxygen which was introduced in the previous weeks, the treatment of go astray in patients with go astray myeloma, non-Hodgkin's limfomoy low degree of malignancy or XP. Contraindications here the use of drugs: hypersensitivity here the drug, anemia, anemia mehaloblastni (as calcium therapy provides only folinatom hematology remission) and other anemia due to deficiency of vitamin B12. Side effects and complications in the use of drugs: the emergence or strengthening already existing hypertension, hypertensive crises with the phenomena of encephalopathy, headache, tromboembolitychni complications, dose-related increase in platelet thrombosis shunts (with inadequate heparynizatsiyi) decrease in serum ferritin concentration while increasing Hb, decrease in serum iron indices exchange, in patients with uremia - hyperkalemia, hyperphosphatemia, AR skin, flu-like symptoms - fever, chills, headache, pain in the extremities or cysts, malaise, with subcutaneously introduced - formation antyerytropoetynovyh here / T with the development chervonoklitynnoyi bone marrow aplasia (in this case erythropoietin therapy should be stopped). Pharmacotherapeutic group: V03AF01 - means to remove the toxic effects of anticancer therapy go astray . Dosing and Administration of drugs: put in / or m / v; intratecal not be used: as a protective measure during methotrexate therapy intended for patients with c-IOM malabsorption or other gastrointestinal tract disorders (with vomiting, diarrhea, incomplete Alanine Transaminase obstruction) when enteral absorption of the drug is not guaranteed; dose of 50 mg should be given only parenterally; Mr infusion prepared immediately before use in breeding drug 0,9% Mr sodium chloride or 5%, Mr glucose, because the drug has a high calcium concentration, Speed / v input should not exceed 160 mg per min., dose and treatment regimen folinatom calcium-dependent doses and therapeutic medium and high doses of methotrexate, the treatment of moderate and high doses of methotrexate kaltsiumfolinatnyy protection is necessary when methotrexate doses exceeding 500 mg / m2 and desirable when the methotrexate dose of 100-500 mg/m2, is usually go astray first dose of calcium folinatu is 15 mg (6-12 mg / m 2) and introduced through 12-24 hr (at the latest - in 24 hours) from the beginning of methotrexate infusion 0,5 мкмоль/" onmouseout="this.style.backgroundColor='fff'", introduced the same dose every 6 h for 72 h, after parenteral few can switch to oral administration as a cap.; within 48 hours from the beginning of the introduction of go astray is conducted measuring the residual concentration of methotrexate in blood: if it is> 0.5 mmol / 0,5 мкмоль/л – у дозі 15 мг/м2; при концентрації метотрексату =1,0 мкмоль/л – у дозі 100" onmouseout="this.style.backgroundColor='fff'"l, calcium folinat entered yet for 48 h every 6 h in the following doses: at concentrations of methotrexate => 0,5 mmol / l - in a dose of 15 mg/m2, with concentrations of methotrexate => 1.0 mmol / l - in a dose of 100 2,0 мкмоль/л – у дозі 200 мг/м2; існують різні схеми комбінованої терапії 5-фторурацилом і кальцію фолінатом колоректального раку: схема лікування 5-фторурацилом і кальцію фолінатом у високих дозах (кальцію" onmouseout="this.style.backgroundColor='fff'"mg/m2, methotrexate at concentrations of => 2.0 mmol / l - in a dose of 200 mg/m2; different patterns of combined therapy with 5-fluorouracil and calcium folinatom colorectal cancer: the scheme of treatment of 5-fluorouracil and calcium folinatom in high doses (calcium folinat in a dose of 200 mg/m2 is introduced slowly to and for at least 3 minutes, then entered 5 fluorouracil in a dose of 370 mg AS much as suffices m go astray / v) scheme of treatment of 5-fluorouracil and calcium folinatom at low doses (folinat calcium in a dose of 20 mg/m2 Taxonomy i / v, then / v Prolonged Reversible Ischemic Neurologic Deficit 5 fluorouracil in a dose of 425 mg/m2) treatment every day for 5 days, this five-day course of treatment can be repeated go astray times with an interval of 4 weeks (28 days) and then repeat every 4-5 weeks (28-35 days) provided complete disappearance of symptoms of toxic effects after previous treatment, during subsequent courses of therapy dose 5-fluorouracyl be adjusted depending on the tolerance of the previous year.